« Back
Home /
Schisandrin A

Schisandrin A

Item no.	HY-N0693-25mg
Manufacturer	MedChem Express
CASRN	61281-38-7
Amount	25 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 50 mg 5 mg
Specific against	other
Purity	99.89
Citations	[1]Li WL, et al. Inhibitory effects of Schisandrin A and Schisandrin B on CYP3A activity. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):163-9.<br/>[2]Li WL, et al. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):187-92.
Smiles	C[C@H]1CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C[C@H]1C
Alias	Schizandrin-A; Wuweizisu-A; Deoxyschizandrin
Available
Product Description	Schisandrin A inhibits CYP3A activity with an IC50 of 6.60 μM and Ki of 5.83 μM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	416.51
Clinical Information	No Development Reported
Manufacturers Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Target	Autophagy; Cytochrome P450; Virus Protease
Manufacturers Target	Autophagy; Cytochrome P450; Virus Protease
Isoform	CYP3
Manufacturers Pathway	Anti-infection; Autophagy; Metabolic Enzyme/Protease
Manufacturers Product type	Natural Products

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Request delivery time